OKYO Pharma Limited ADR OKYO 深 滬
已收盤 10-03 16:00:00 美东时间
2.05
+0.070
+3.54%
華盛通- 最 高2.189
- 今 開2.01
- 成交量 23.49万股
- 最 低 2.01
- 昨 收 1.98
- 總市值 7710.19万
- 52周最高 3.349
- 市盈率 靜 --
- 換手率 0.62%
- 52周最低 0.9016
- 委 比 -97.04%
- 總股本 3761.07万
- 歷史最高 7.00
- 量 比 2.37
- 振 幅 9.04%
- 歷史最低 0.8075
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain
OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe
09-22 20:37
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
OKYO Pharma announced plans to advance the next stage of clinical development for its drug candidate urcosimod to treat neuropathic corneal pain (NCP). Following positive Phase 2 trial results showing 75% of patients experienced significant pain reduction, the company is conducting a multiple-ascending-dose trial to enroll approximately 100 NCP patients, identify the optimal dose for future trials, and further study urcosimod's properties. Additi...
09-22 12:30
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Limited received $1.9 million in non-dilutive funding to accelerate the development of urcosimod, its lead drug candidate for treating neuropathic corneal pain (NCP), a debilitating condition with no FDA-approved therapy. The funding supports clinical milestones, R&D expansion, and regulatory progress, enabling the company to pursue its mission without diluting shareholder value. Urcosimod, a lipid-conjugated chemerin peptide agonist,...
07-17 13:00
OKYO Pharma Announces Top-Line Data From Recently Closed 18-Patient Phase 2 Trial Of Urcosimod To Treat NCP
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly
07-16 21:22
OKYO Pharma to Present at the Bio International Convention
OKYO Pharma announced that its CEO, Dr. Gary S. Jacob, will present at the 2025 Bio International Convention in Boston about urcosimod, a drug candidate for treating neuropathic corneal pain (NCP). NCP causes severe eye discomfort due to nerve damage and inflammation, affecting tens of thousands globally. Urcosimod, a long-acting drug targeting eye inflammation and pain, showed significant results in Phase 2 trials for dry eye disease and is now ...
06-11 12:30
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On May 19, ...
05-19 19:27
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment
OKYO Pharma (NASDAQ:OKYO) said on Monday that urcosimod, its neuropathic corneal pain treatment, has shown to be stable for over two and a half years in single-use ampoules used for administration to ...
03-31 22:01
美股大行评级 | 潜在涨幅49%！PayPal获机构上调目标价至117美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1096044530357866496.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Dakota Gold(DC)"跑赢大市"评级，目标价从6美元升至7.5美元</p> <p>• 杰富瑞：维持Compass Therapeutics(CMPX)"买入"评级，目标价从7美元升至8美元</p
02-11 18:08
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence
OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an announcement. On...
01-31 20:29
